Safety and tolerability
The Sativex clinical program has so far involved over 1500 patients with MS in placebo controlled trials and long-term open label studies in which some patients used up to 48 sprays per day (1).
Common adverse reactions (1)
The most commonly reported adverse reactions in the first four weeks of exposure were dizziness, which occurred mainly during the initial titration period, and fatigue (see Table 1). These reactions are usually mild to moderate and resolve within a few days even if treatment is continued.
When the recommended dose titration schedule was used, the incidence of dizziness and fatigue in the first four weeks was much reduced.
Table 1. Adverse events with a plausible relationship to Sativex, from placebo-controlled trials in patients with MS. Some of these adverse events may be part of the underlying condition.
|MedDRa SOC||Very Common
≥ 1/100 to < 1/10
≥ /1000 to < 1/100
|Infections and infestations||Pharyngitis|
|Metabolism and nutrition disorders||Anorexia (including appetite decreased); appetite increased|
|Psychiatric disorders||Depression; disorientation; dissociation; euphoric mood||Hallucination (unspecified, auditory, visual); illusion; paranoia; suicidal ideation; delusional perception*|
|Nervous system disorders||Dizziness||Amnesia; balance disorder; disturbance in attention; dysarthria; dysgeusia; lethargy; memory impairment somnolence||Syncope|
|Eye disorders||Vision blurred|
|Ear and labyrinth disorders||Vertigo|
|Cardiac disorders||Palpitations; tachycardia|
|Respiratory, thoracic and mediastinal disorders||Throat irritation|
|Gastrointestinal disorders||Constipation; diarrhoea; dry mouth; glossodynia; mouth ulceration; nausea; oral discomfort; oral pain; vomiting||Abdominal pain (upper); oral mucosal discolouration*; oral mucosal disorder; oral mucosal exfoliation*; stomatitis; tooth discolouration|
|General disorders and administration site conditions||Fatigue||Application site pain; asthenia; feeling abnormal; feeling drunk; malaise||Application site irritation|
|Injury, poisoning and procedural complaints||Fall|
*Reported in long-term open-label studies
Drug interactions (1)
During the clinical trials of Sativex, patients remained on their existing medications.
However care should be taken with hypnotics, sedatives and drugs with potential sedating effects as there may be an additive effect on sedation and muscle relaxing effects.
Also, although there has been no greater rate of adverse events in patients already taking anti-spasticity agents when they also take Sativex, care should be taken when co-administering Sativex with anti-spasticity agents, since a reduction in muscle tone and power may occur, leading to a greater risk of falls.
Refer to the SmPC for details of interactions with other medicinal products and other forms of interaction.
Abuse potential (1)
In a study designed to identify its abuse potential, Sativex at a dose of four sprays taken at one time did not differ significantly from placebo.
People with MS spasticity who take Sativex for prolonged periods do not increase their daily dose, and also do not develop any withdrawal syndrome if the treatment is stopped suddenly. Sativex therefore has limited abuse potential in patients at the recommended dose. However patients who have a history of substance abuse, may be more prone to abuse Sativex.
- Sativex Summary of Product Characteristics.